Overview
Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms. It is one of the most common skin and mucous membrane antiseptic agents in use today. The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain. Topical chlorhexidine for disinfection, as well as oral rinses for dental use, carries activity against a broad range of pathogens including bacteria, yeasts, and viruses. Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s and was introduced to the US in the 1970s. The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use of this product. Other formulations of chlorhexidine continue to be available.
Background
Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms. It is one of the most common skin and mucous membrane antiseptic agents in use today. The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain. Topical chlorhexidine for disinfection, as well as oral rinses for dental use, carries activity against a broad range of pathogens including bacteria, yeasts, and viruses. Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s and was introduced to the US in the 1970s. The FDA withdrew its approval for the use of chlorhexidine gluconate topical tincture 0.5%, due to a significant number of reports concerning chemical and thermal burns associated with the use of this product. Other formulations of chlorhexidine continue to be available.
Indication
Chlorhexidine is available over-the-counter in various formulations (e.g. solution, sponge, cloth, swab) as a topical antiseptic to sanitize prior to surgeries and/or medical procedures. Dental formulations, available by prescription only, include an oral rinse indicated for the treatment of gingivitis and a slow-release "chip" which is inserted into periodontal pockets and is indicated for the reduction of pocket depth in adult patients with periodontitis as an adjunct therapy to dental scaling and root planing procedures.
Associated Conditions
- Aphthous ulcer
- Catarrh of the throat
- Chemotherapy Induced Oral Mucositis
- Chronic Wounds
- Decubitus Ulcer
- Dental Cavity
- Dysphagia
- Eczema infected
- Foeter Ex Ore
- Gingival Bleeding
- Gingival Diseases
- Gingivitis
- Glossitis
- Hoarseness
- Infection
- Infectious Periodontal Diseases
- Injury Throat
- Mild to Moderate Inflammatory Reaction of the Oral Cavity
- Mild to Moderate Inflammatory Reaction of the Pharynx
- Mouth injury
- Mucositis
- Neurodermatitis
- Ocular Inflammation
- Ocular Irritation
- Oral Aphthous Ulcer
- Pain
- Periodontitis
- Pharyngitis
- Plaque, Dental
- Postoperative Wound Infection
- Purulent Gingivitis
- Radiation Mucositis
- Red eye
- Ringworm
- Skin Infections
- Sore Throat
- Stomatitis
- Surgical Wounds
- Tissue Damage
- Tonsillitis
- Ulcers, Leg
- Wound Infections
- Bacterial skin infections
- Dry, cracked skin
- Gum pain
- Moderate Gingivitis
- Oral infections
- Oral lesions
- Recurrent Oral fungal infection
- Severe Gingivitis
- Superficial Wounds
- Throat disinfection
- Tongue inflammation
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2019/02/12 | Phase 3 | UNKNOWN | |||
2019/02/11 | Phase 2 | Completed | Amirhossein Farahmand | ||
2018/12/26 | Phase 1 | Withdrawn | Gladwin, Mark, MD | ||
2018/12/12 | Phase 2 | UNKNOWN | |||
2018/11/15 | Phase 4 | UNKNOWN | |||
2018/10/09 | Phase 3 | Not yet recruiting | |||
2018/10/09 | Phase 3 | UNKNOWN | |||
2018/09/26 | Phase 2 | Completed | |||
2018/09/04 | Not Applicable | UNKNOWN | |||
2018/08/21 | Phase 4 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||